New release on opnMe.com - Access our BRD9 and BRD7/BRD9 inhibitors for free to advance your research

19 March 2018

Boehringer Ingelheim’s well-characterized, potent and selective BRD9 inhibitor BI-9564 and the dual BRD7/BRD9 inhibitor BI-7273 are now available on opnMe.com. Both were developed in collaboration with the Structural Genomics Consortium (SGC).
We are happy send you 5 mg of both inhibitors and a negative control completely free of charge for your research. You will own all results you will generate with the tool compounds and may use them for own publications.
Start your new research project today and see where the results may take you.

3-D structures of BI-9564 and BI-7273

Figure: 3-D structures of BI-9564 and BI-7273

Subscribe to our newsletter to stay updated on our regular additions to opnMe.com.
About BI-9564 and BI-7273:
BI-9564 binds with high affinity to BRD9 K_D(BRD9, ITC) = 14 nM and with lower affinity to closely related BRD7 K_D(BRD7, ITC) = 239 nM. CECR2 was the only other identified off-target (K_D(CECR2, ITC) = 258 nM), but with no effect in cells at 1 µM (FRAP assay). BI-9464 is completely negative on BET family members in the AlphaScreen (>100 µM).
BI-7273 is a potent dual BRD7/BRD9 inhibitor with 30 fold better potency in the BRD7 AlphaScreen assay compared to our more selective BRD9 inhibitor BI-9564
About opnMe:
opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives and enable new disease biology in areas of high unmet medical need by sharing well-characterized, including many best-in-class, pre-clinical tool compounds. The molecules have been designated either as ‘Molecules to Order’, which are offered for free without entering into intellectual property discussions. ‘Molecules for Collaboration’ offers the opportunity to initiate joint research projects. Scientists interested in these molecules are invited to submit a research proposal. If the proposal is chosen, the science will be developed together with Boehringer Ingelheim scientists as part of a bi-lateral collaboration.